Skip to main content
SpringerLink
Log in

FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Relapsed or refractory adult acute lymphoblastic leukemias (ALL) have poor prognosis. The strategy for treating these patients is through reinduction chemotherapy followed by allogeneic stem cell transplantation, provided that the toxicity of the salvage regimen is acceptable. Twenty three patients with relapsed/refractory adult ALL were treated with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA). Five patients had primary refractory disease, and 18 were in first relapse. Nine (39.1%) patients achieved complete remission (CR) following salvage therapy, whereas 13 (56.5%) patients were refractory, and one patient died in aplasia due to infection. In patients achieving remission, the median time to reach absolute neutrophil count (ANC) more than 0.5×109/l and 1×109/l was 20 (range 16–25) and 24 (range 20–28) days from the start of chemotherapy, respectively. Platelet levels of more than 20×109/l and 100×109/l were achieved in a median time of 23 (range 19–25) and 33 (range 28–39) days, respectively. Fever more than 38.5°C was observed in 18 of 23 patients (78.2%), 13 had fever of unknown origin, and 5 had documented infections. Nonhematological side effects, consisting mainly of mucositis (18/23 or 78.2%) and transient liver toxicity increase (10/23 or 43.4%), were generally tolerated. All nine patients who achieved CR received a second course with FLAG-IDA, and seven patients underwent allogeneic stem cell transplantation (four from a matched donor, one from a mismatched donor, and two from an unrelated donor), while two did not reach that stage due to early relapse from CR. The median overall survival (OS) for all 23 patients was 4.5 (range 1–38) months; for the nine responders, the disease-free survival (DFS) and the OS were 6 (range 3–38) and 9 (7–38) months, respectively; the seven patients who received allogeneic stem cell transplantation had a DFS of 10 (range 7–38) months. In our experience, FLAG-IDA is a well-tolerated regimen in relapsed/refractory ALL patients; the toxicity is acceptable, enabling patients who have achieved CR to receive allogeneic transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Atra A, Gerrard M, Hobson R, Imeson J, Hann I, Pinkerton C (2001) Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin’s lymphoma treated with the UKCCSG 9003/9002 protocols. Br J Haematol 112:965–968

    Article  PubMed  CAS  Google Scholar 

  2. Camera A, Annino L, Chiurazzi F, Fazi P, Cascavilla N, Fabbiano F, Marmont F, Di Raimondo F, Recchia A, Vignetti M, Rotoli B, Mandelli F (2004) GIMEMA ALL-Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. Haematologica 89:145–153

    PubMed  CAS  Google Scholar 

  3. Estey E, Thall P, Andreff M, Beran M, Kantarjian H, O’Brien S, Escudier S, Robertson LE, Koller C, Kornblau S et al (1994) Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodisplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671–678

    PubMed  CAS  Google Scholar 

  4. Freund M, Diedrich H, Ganser A, Gramatzki M, Heil G, Heyll A, Henke M, Hiddemann W, Haas R, Kuse R et al (1992) Treatment of relapsed or refractory adult acute lymphocytic leukemia. Cancer 69:709–716

    Article  PubMed  CAS  Google Scholar 

  5. Gandhi V, Estey E, Keating M, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116–124

    PubMed  CAS  Google Scholar 

  6. Giona F, Testi AM, Annino L, Amadori S, Arcese W, Camera A, Di Montezemolo LC, Ladogana S, Liso V, Meloni G et al (1994) Treatment of primary refractory and relapsed acute lymphoblastic leukemia in children and adults: the GIMEMA-AIEOP experience. Br J Haematol 86:55–61

    PubMed  CAS  Google Scholar 

  7. Keating M, O’Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165–1171

    PubMed  CAS  Google Scholar 

  8. Koller C, Kanatrjian H, Thomas D, O’Brien S, Rios M, Kornblau S, Murphy S, Keating M (1997) The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 11:2039–2044

    Article  PubMed  CAS  Google Scholar 

  9. Martino R, Bellido M, Brunet S, Sureda A, Peyret M, Guardia R, Altes A, Domingo-Albos A, Sierra J (1998) Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia. Bone Marrow Transplant 21:1023–1027

    Article  PubMed  CAS  Google Scholar 

  10. Martino R, Bellido M, Brunet S, Altes A, Sureda A, Guardia R, Aventin A, Nomdedeu J, Albos A, Sierra J (1999) Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial. Haematologica 84:505–510

    PubMed  CAS  Google Scholar 

  11. Michelutti A, Michieli M, Damiani D, Melli C, Ermacora A, Grimaz S, Candoni A, Russo D, Fanin R, Baccarani M (1997) Effect of fludarabine and arabinosylcytosine on multidrug-resistance cells. Haematologica 82:143–147

    PubMed  CAS  Google Scholar 

  12. Montillo M, Tedeschi A, Centurioni R, Leoni P (1997) Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Leuk Lymphoma 25:579–582

    PubMed  CAS  Google Scholar 

  13. Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V (2003) FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single center experience. Ann Hematol 82:231–235

    PubMed  CAS  Google Scholar 

  14. Rosen P, Rankin C, Head D, Boldt D, Luthardt F, Norwood T, Pugh R, Karenes C, Appelbaum (2000) A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia. Leuk Res 24:183–187

    Article  PubMed  CAS  Google Scholar 

  15. Suki S, Kantarjian H, Gandhi V, Estey E, O’Brien S, Bera M, Rios MB, Plunkett W, Keating M (1993) Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer 72:2155–2160

    Article  PubMed  CAS  Google Scholar 

  16. Thomas D, Kantarjian H, Smith T, Koller C, Cortes J, O’Brien S, Giles F, Gajewski J, Pierce S, Keating M (1999) Primary refractory and relapsed adult acute lymphoblastic leukemia. Characteristics, treatment results and prognosis with salvage treatment. Cancer 86:1216–1230

    Article  PubMed  CAS  Google Scholar 

  17. Weiss M, Drullinsky P, Maslak P, Schenberg D, Golde D (1998) A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia 12:865–868

    Article  PubMed  CAS  Google Scholar 

  18. World Health Organization (1979) A handbook for reporting results of cancer patients. WHO, Geneva

    Google Scholar 

Download references

Acknowledgements

This work was supported by Ministero dell’Istruzione dell’Università e della Ricerca (MIUR); we thank Ms. M.V.C. Pragnell, BA, for language assistance in the preparation of the manuscript.

Author information

Authors and Affiliations

  1. Hematology Section, DIMIMP Department, University of Bari, Piazza Giulio Cesare 11, 70124, Bari, Italy

    G. Specchia, D. Pastore, P. Carluccio, A. Liso, A. Mestice, R. Rizzi, L. Ciuffreda, G. Pietrantuono & V. Liso

Authors
  1. G. Specchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Pastore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Carluccio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Liso
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Mestice
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Rizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. Ciuffreda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Pietrantuono
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V. Liso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Specchia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Specchia, G., Pastore, D., Carluccio, P. et al. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol 84, 792–795 (2005). https://doi.org/10.1007/s00277-005-1090-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-1090-9

Keywords

Search

Navigation